Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK2330672 in Healthy Japanese Volunteers
NCT02801981Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of linerixibat in cholestasis (4 arms), sponsored by GSK. Primary endpoints: Number of Subjects with Adverse events (AE) at 5 weeks, Safety as assessed by blood pressure at 5 weeks and 7 more. Started Jun 2016; status: completed.
02
Drugs
linerixibat
03
Conditions
cholestasis
Beyond the preview
Go deeper on NCT02801981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02801981.